Simvastatin-induced rhabdomyolysis: A case study on clinical-decision making based on the evidence-based medicine approach

Archives of Medical Science

Volumn 3, Issue 3, 2007, Pages 267-271

  Koskinas, Konstantinos ^a   Tzellos, Thrasyvoulos G ^b   Gougoulias, Kyriakos ^a   Gougoulias, Georgios ^a   Papakonstantinou, Christos ^a   Kouvelas, Dimitrios ^b  

^a General Hospital of Halkidiki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Case report; Evidence based medicine; Rhabdomyolysis; Simvastatin; Statin safety

Indexed keywords

CREATINE KINASE; METFORMIN; SIMVASTATIN; STATINE DERIVATIVE; VALSARTAN;

AGED; ARTICLE; CASE REPORT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CREATINE KINASE BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MEDICAL EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; RHABDOMYOLYSIS;

EID: 35448999294     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lane R, Phillips M. Rhabdomyolysis. BMJ 2003; 327: 115-6.
2. Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Intern Med 2007; 18: 90-100.
3. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-107.
4. Bhatia V. Massive Rhabdomyolysis with simvastatin precipitated by amoxicillin. J Postgrad Med 2004; 50: 234-5.
5. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
6. Myocardial infarction redefined - a consensus of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-13.
7. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
10. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-30.
11. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99: 95-112.
12. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: 39-43.
13. May C, Greenough A. Pulmonary hypoplasia and congenital renal anomalies. Arch Med Sci 2006; 2: 6-9.
14. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-72.
15. Tiwari A, Bansal V, Clugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf 2006; 5: 651-66.
16. Sochman J, Podzimkova M. Not all statins are alike: induced rhabdomyolysis on changing from one statin to another one. Int J Cardiol 2005; 99: 145-6.
17. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28: 26-35.
18. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006; 260: 305-19.
19. Neil J, Stone MD. Stopping statins. Circulation 2004; 110: 2280-2.